Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-Weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study.
Sosana DelimpasiMaria Victoria MateosHolger W AunerMaria GavriatopoulouMeletios- Athanasios DimopoulosHang QuachHalyna PylypenkoRoman HájekXavier LeleuTuphan Kanti DolaiDinesh Kumar SinhaChristopher P VennerReuben BenjaminMamta Krishnan GargVadim DoroninYair LevyPhillipe MoreauYi ChaiMelina ArazyJatin ShahSharon ShachamMichael G KauffmanPaul Gerard RichardsonSebastian GrosickiPublished in: American journal of hematology (2021)